France finally has a full budget for 2026, ending months of stasis, and providing a degree of certainty to industry. However, especially for pharma, continual price cuts threaten the sustainability of France as an investment destination, although the reindustrialisation incentives…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta showcases strong innovation and global ambitions through major licensing deals, IPO activity, and clinical advancements. Notable transactions include Shimai Pharma’s…
Ajay Mahipal of India-focused healthcare impact and venture capital investment platform HealthKois argues that India’s life-sciences ecosystem is approaching an inflection point. Having built its reputation on manufacturing scale, the…
Drawn from Healthcare & Life Sciences Review Denmark 2025, this selection captures the major forces now reshaping one of Europe’s most dynamic life science hubs. From Denmark’s bid to double…
The opportunity now is to ensure that the policy and access environment evolves at the same pace as the science Europe possesses one of the world’s strongest scientific ecosystems, yet its ability to translate scientific excellence into timely and equitable patient access is becoming the defining challenge for the region’s competitiveness. As AbbVie Europe enters a new chapter under Rami…
Michala Fischer-Hansen, EVP and Head of Europe & International Markets at Lundbeck, discusses her return to pharma and Lundbeck’s focused innovator strategy, centred on neuroscience, R&D and growth through regional…
Recordati Rare Diseases aims to be a trusted partner in helping patients with rare diseases reach diagnosis and appropriate care sooner Rapid access to innovation alone does not solve the…
Boston and the Bay Area are globally renowned life science hubs, but beyond these more well-known centers of excellence lies a dense network of states and cities with enticing and…
Rainer Westermann offers a sobering take on Europe’s declining global status as both a source and recipient of biopharmaceutical innovation. He argues that the time for a paradigm shift in…
In 2025, just 318 US biotech deals closed in Q2 – the lowest in a decade – even as mega-rounds propped up total investment volumes. For a sector that was…
With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals –…
When it comes to Denmark’s flourishing local biotech scene, the country is again clearly punching far above its weight. The EU member state has already managed to muster world-class expertise…
Whilst G7 countries have long been the traditional homes of pharmaceutical innovation, there is increased global competition, and a real risk that this longstanding leadership will be lost without concerted…
See our Cookie Privacy Policy Here
